02.120

030 03439
48-03280-01
Ex 8/31/84

MOUNT SINAI MEDICAL CENTER R (F.P)

950 North Twelfth Street
Milwaukee WI 53201

DANIEL A. KANE
President

July 30, 1984

Oct 2 - III

Applicant... Dec. c.d. 1.7.80 Two
Check No... Emergency Amdt
Amount Fee Enclosed... Renewal
Type of Fee... Renewal
Date Check Received... fee to
Received By... Jacque follow

Material Licensing Branch
U.S. Nuclear Regulatory Commission
Region III
799 Roosevelt Road
Glen Ellyn, Illinois 60137

Re: License number 48-03280-01

In accordance with the criteria specified by the Nuclear Regulatory Commission, Mount Sinai is hereby requesting renewal of license number 48-03280-01. The facilities, services and authorized users covered by this license are as described in the license application dated December 1, 1978, the ALARA Program document dated October 1, 1981, and the below listed letters:

July 10, 1979
October 14, 1980
June 9, 1981
October 22, 1981
March 29, 1982
December 13, 1982
January 6, 1983
October 31, 1983
April 20, 1984
June 19, 1984

U.S.N.R.C.
FEE MGMT. BRANCH
'85 OCT -3 P12:06
RECEIVED

Copies of these documents are on file with your office.

This letter has four (4) attachments.

1. Attachment 1 contains an array of modifications to possession limits and named users;

2. Attachments 2 and 3 supersede the description of services and facilities contained in the January 16, 1979 and February 22, 1980 letters, respectively.

3. Attachment 4 pertains to the June 20, 1984 amendment request for the disposal of experimental animal waste by incineration at this facility.

RECEIVED
JUL 30 1984
REGION III

950 North Twelfth Street, P.O. Box 342 • Milwaukee, Wisconsin 53201 • 414/289-8001

Partial Appl
FEE EXEMPT

Affiliated with
The University of Wisconsin Medical School • The Medical College of Wisconsin • Marquette University School of Dentistry

ATTACHMENT 1

Modification to Possession Limits and Named Users

A. For IODINE-131 AS IODIDE FOR TREATMENT OF THYROID CARCINOMA, increase maximum possession limit to 400 millicuries.

B. Under Items 6, 7, and 8, add:

6. Byproduct, source, and/or special nuclear material.

U. Selenium - 75

7. Chemical and/or physical form

U. Any

8. Maximum amount that licensee may possess at any one time.

U. 25 millicuries.

C. Under Item 8, maximum amount that licensee may possess at any one time under this license,

1. increase sub-item F. to 10 millicuries of each,
2. increase sub-item H. to 5,000 millicuries,
3. increase sub-item O. to 100 millicuries,
4. increase sub-items Q, R, S, and T to 25 millicuries each.

D. Under Item 12, authorized users, add

1. Dr. Michael W. Mosesson, M.D., for materials in sub-items 6F, and H through U., for in vitro and animal research. Dr. Mosesson was a named user on the license of Downstate Medical Center, Brooklyn, New York, license number NY82-78.

2. Dr. Ranjini B. Gandhavadi, M.D., as an authorized user for Group VI.

3. Dr. B.R. Elejalde, M.D., for H-3, C-14, S-35, Se-75, and I-125 as prelabelled compounds; Cr-51; for in-vitro and animal research.

4. Dr. Carl Christensen, Ph.D., for H-3, C-14, I-125, and Tc-99m in all forms; Xe-133 gas or in saline solution; and Cr-51, Sr-85, Nb-95, Ru-103, and Ce-141 as microspheres, for in vitro and animal research.

5. Dr. Mark J. Melancon, Ph.D., for H-3, C-14, S-35, I-125, and I-131 as pre-labelled compounds; for in-vitro and animal research.

6. Dr. David L. Amrani, Ph.D., for H-3, C-14, S-35, Se-75, I-125, and I-131 as pre-labelled compounds; Cr-51; I-125 and I-131 for radio-iodination procedures; for in-vitro and animal research.

7. Dr. Gene A. Homandberg, Ph.D., for H-3, C-14, S-35, Se-75, I-125, and I-131 as pre-labelled compounds; Cr-51, I-125 and I-131 for radio-iodination procedures; for in-vitro and animal research.

8. Dr. Laurence D. Tempelis, M.D., for H-3, C-14, S-35, Cr-51, Se-75, Sr-85, Nb-95, Tc-99m, Ru-103. I-125, I-131, and Xe-133; for in vitro and animal research.

   A copy of license no. 82-110-078 and NRC-313M forms for proposed authorized users (2) through (8) are a part of this attachment.

NRC FORM 313M SUPPLEMENT A
(9-81)

U.S. NUCLEAR REGULATORY COMMISSION

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER	2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE
Ranjini B. Gandhavadi , M.D.	Wisconsin

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
American Board of Radiology	Radiation Therapy	June, 1982

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES *(Hours)* C	SUPERVISED LABORATORY EXPERIENCE *(Hours)* D
a. RADIATION PHYSICS AND INSTRUMENTATION	June, 1978-June, 1982		4 years
b. RADIATION PROTECTION	Qualified and passed American Board of Radiology		
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY			
d. RADIATION BIOLOGY			
e. RADIOPHARMACEUTICAL CHEMISTRY			

5. EXPERIENCE WITH RADIATION. *(Actual use of Radioisotopes or Equivalent Experience)*

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
Cs-137	100 ng.	As a resident at Radiation Oncology; Medical College of Wisconsin, Milwaukee, Wisconsin 53226	1978-82	For treating patients with intracavitory and Heyman's capsules
Co-60	Teletherapy		1978-82	For treating patients

NRC FORM 313M SUPPLEMENT B
(9-81)

U. S. NUCLEAR REGULATORY COMMISSION

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

FULL NAME

Ranjini B. Gandhavadi , M.D.

STREET ADDRESS

950 North 12th Street

CITY | STATE | ZIP CODE

Milwaukee, Wisconsin 53201

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS *(Additional information or comments may be submitted in duplicate on separate sheets.)* D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	–	
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME	–	
	LIVER FUNCTION STUDIES	–	
	FAT ABSORPTION STUDIES	–	
	KIDNEY FUNCTION STUDIES	–	
	IN VITRO STUDIES	–	
OTHER		–	
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING	–	
P-32	EYE TUMOR LOCALIZATION	–	
Se-75	PANCREAS IMAGING	–	
Yb-169	CISTERNOGRAPHY	–	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	–	
OTHER		–	
Tc-99m	BRAIN IMAGING		
	CARDIAC IMAGING	–	
	THYROID IMAGING	–	
	SALIVARY GLAND IMAGING	–	
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION	–	
	LIVER AND SPLEEN IMAGING	–	
	LUNG IMAGING	–	
	BONE IMAGING	–	
OTHER			

RECEPTOR STATEMENT *(Continued)*

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN *(Continued)*

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS *(Additional information or comments may be submitted in duplicate on separate sheets.)* D
P-32 *(Soluble)*	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	-	Treated patients with Co-60 unit at West Allis Hospital for about 6 months, average 20-25- patients per day.
P-32 *(Colloidal)*	INTRACAVITARY TREATMENT	-	
I-131	TREATMENT OF THYROID CARCINOMA		
	TREATMENT OF HYPERTHYROIDISM	-	
Au-198	INTRACAVITARY TREATMENT	-	
Co-60 or Cs-137	INTERSTITIAL TREATMENT	-	
	INTRACAVITARY TREATMENT	20-25	
I-125 or Ir-192	INTERSTITIAL TREATMENT	5-10	
Co-60 or Cs-137	TELETHERAPY TREATMENT	150	
Sr-90	TREATMENT OF EYE DISEASE	2	
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR	-	
Sn-113/ In-113m	GENERATOR	=	
Tc-99m	REAGENT KITS	-	
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

Trained in therapeutic radiology at Medical College of Wisconsin 1978-82

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR
James D. Cox, M.D.

b. NAME OF INSTITUTION
Medical College of Wisconsin

c. MAILING ADDRESS Radiation Oncology
8500 W. Wisconsin Avenue

d. CITY
Milwaukee, Wisconsin

5. MATERIALS LICENSE NUMBER(S)
48-04193-01

6. PRECEPTOR'S SIGNATURE
James D. Cox, MD

7. PRECEPTOR'S NAME *(Please type or print)*
James D. Cox

8. DATE
July 11, 1984

NRC FORM 313M SUPPLEMENT 8
(9-81)

GPO 890-813

CONVERSATION RECORD

TIME 8:30A DATE 9/27/85

TYPE ☐ VISIT ☐ CONFERENCE ☐ TELEPHONE ☐ INCOMING ☐ OUTGOING

Location of Visit/Conference:

NAME OF PERSON(S) CONTACTED OR IN CONTACT WITH YOU	ORGANIZATION (Office, dept., bureau, etc.)	TELEPHONE NO.
Robert Black	Mt. Sinai Medical Ctr	(414) 289-8634

SUBJECT Renewal of Lic. No. 48-03280-01

ROUTING	
NAME/SYMBOL	INT

SUMMARY Mr Black called requesting status of application I told him that he will be receiving a deficiency letter w/in the next week. We also discussed items specified in letter.

Mr Black requested that a physician listed in their renewal application be added ASAP due to departure of physician currently authorized for Group VI. Physician to be added is Ranjini B. Gandhavadi, M.D. (Board Certified in Diag Radiology).

I will initiate administrative amendment on our end with "no incoming control."

ACTION REQUIRED Initiate administrative amendment to add Dr. Gandhavadi to lic # 48-03280-01 prior to issuance of renewal.

NAME OF PERSON DOCUMENTING CONVERSATION	SIGNATURE	DATE
	P. J. Hilton	9/27/85

ACTION TAKEN

SIGNATURE	TITLE	DATE

50271-101 CONVERSATION RECORD OPTIONAL FORM 271 (12-76) DEPARTMENT OF DEFENSE